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Abstract
Objectives
The aim of this study was to systematically collate and appraise the available evidence
regarding the associations between small, dense low-density lipoprotein (sdLDL) and inci-
dent coronary heart disease (CHD), focusing on cholesterol concentration (sdLDL-C) and
sdLDL particle characteristics (presence, density, and size).
Background
Coronary heart disease (CHD) is the leading cause of death worldwide. Small, dense low-
density lipoprotein (sdLDL) has been hypothesized to induce atherosclerosis and subse-
quent coronary heart disease (CHD). However, the etiological relevance of lipoprotein parti-
cle size (sdLDL) versus cholesterol content (sdLDL-C) remains unclear.
Methods
PubMed, MEDLINE, Web of Science, and EMBASE were systematically searched for stud-
ies published before February 2020. CHD associations were based on quartile comparisons
in eight studies of sdLDL-C and were based on binary categorization in fourteen studies of
sdLDL particle size. Reported hazards ratios (HR) and odds ratios (OR) with 95% confi-
dence interval (CI) were standardized and pooled using a random-effects meta-analysis
model.
Results
Data were collated from 21 studies with a total of 30,628 subjects and 5,693 incident CHD
events. The average age was 67 years, and 53% were men. Higher sdLDL and sdLDL-C
levels were both significantly associated with higher risk of CHD. The pooled estimate for
the high vs. low categorization of sdLDL was 1.36 (95% CI: 1.21, 1.52) and 1.07 (95% CI:
1.01, 1.12) for comparing the top quartiles versus the bottom of sdLDL-C. Several studies
suggested a dose response relationship.
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Conclusions
The findings show a positive association between sdLDL or sdLDL-C levels and CHD,
which is supported by an increasing body of genetic evidence in favor of its causality as an
etiological risk factor. Thus, the results support sdLDL and sdLDL-C as a risk marker, but
further research is required to establish sdLDL or sdLDL-C as a potential therapeutic marker
for incident CHD risk reduction.
Introduction
Coronary heart disease (CHD) is the leading cause of death worldwide, with an estimated 7.4
million people having died from CHD in 2015 [1]. In the USA, although mortality rate has
been decreasing, the prevalence of CHD is predicted to rise from 6.8% (2015) to 8.2% (2035)
[2]. With the projected increased burden, it is increasingly important to identify risk factors
that can help to identify high CHD-risk individuals. CHD is primarily caused by atherosclero-
sis and the resulting inflammation of the coronary arteries [3]. Although low-density lipopro-
tein cholesterol (LDL-C) is a well-studied risk factor, there is a growing body of evidence that
challenges the conventional view of LDL-C as the most relevant biomarker for CHD. Firstly,
individuals with normal range LDL-C have been found to still develop CHD [4] and secondly,
several observational studies have found that adjusting for other lipoproteins substantially
attenuates the association of LDL-C [5–7], which suggests that other novel lipoproteins may
have more discriminatory potential.
Circulating lipoproteins vary in size, density, and composition, and various laboratory
methods have been developed to separate LDL fractions into subfractions. The first method,
ultracentrifugation, separated LDL particles based on flotation rate into generally four sub-
classes, LDL I (density = 1.025–1.034 g/ml), II (1.034–1.044 g/ml), III (1.044–1.060 g/ml), and
IV (>1.060 g/ml) where LDL I and II characterizes phenotype A (large buoyant LDL), and
LDL III and IV characterizes phenotype B (small, dense LDL) [8]. Another analytical method
is gradient gel electrophoresis (GGE) under nondenaturing conditions, which separates LDL
particles by their size and shape. Studies using GGE define four subclasses as well LDL I (large
LDL, peak diameter 26.0–28.5 nm), LDL II (intermediate LDL, 25.5.-26.4 nm), LDL III A and
B (small LDL, 24.2–25.5 nm), and LDL IV A and B (very small LDL, 22.0–24.1 nm) [9]. There
is a strong correlation between density and size of particles analyzed by ultracentrifugation
and GGE respectively. Other methods include NMR which subclassifies LDL particles based
on size and automated homogeneous assays, which separates sdLDL fractions with a density
from 1.044 to 1.063 g/ml [10,11].
Small, dense low-density lipoproteins (sdLDL) have been increasingly studied as a better
marker for cardiovascular disease outcomes. They were initially described by Krauss to be
associated with relative increases in plasma triglyceride and apolipoprotein B and posited to
potentially underlie a familial predisposition to CHD [12]. Austin has produced a large body
of research further linking triglycerides and sdLDL [13] as well as positing sdLDL as a risk fac-
tor for CHD, albeit based only on case control and cross-sectional studies [14]. The number of
sdLDL particles was reported to be a more sensitive biomarker for metabolic syndrome com-
pared to LDL-C [15], and sdLDL-cholesterol (sdLDL-C), the free cholesterol content within
sdLDL particles, was reported to be a better marker for assessment of CHD than total LDL-C
[16]. Moreover, sdLDL is currently accepted as a risk factor for CVD by the National Choles-
terol Education Program [17]. While there is high validity between sdLDL particle
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measurement analyzed by ultracentrifugation and gel electrophoresis [18], the agreement
between these conventional methods and nuclear magnetic resonance is yet to be validated. Its
physical and biochemical properties have been hypothesized and widely believed to facilitate
its atherogenic potential.
The origins of sdLDL formation are hypothesized to be from the delipidation of triglycer-
ide-rich lipoproteins catalyzed by lipoprotein lipase and hepatic lipase enzymes [19], and
sdLDL has been associated with elevated plasma triglyceride levels, reduced HDL cholesterol,
and high hepatic lipase activity [20]. In fact, evidence of the metabolic role that increased
plasma triglyceride levels has on circulating sdLDL levels has been elucidated [21]. The small
size of sdLDL particles favors their penetration into the arterial wall where they can instigate
cholesterol accumulation and their susceptibility to oxidation attracts inflammatory factors
which increase the probability of atherogenesis [22,23]. Further, the circulation time of sdLDL
is longer than that of LDL particles, which suggests that there are more opportunities for
sdLDL to play an important role in the development and growth of atherosclerotic plaques
[24,25].
Research has focused on studying either the levels of sdLDL particle concentrations or the
levels of cholesterol within sdLDL particles (sdLDL-C); however only one study has simulta-
neously looked at both. They found that elevated sdLDL-C concentration, but not sdLDL par-
ticle concentration, was found to be a significant marker of CHD risk [26]. The aim of this
study was to systematically review and critically appraise existing evidence and quantify both
the associations between sdLDL particle concentration and CHD and sdLDL-C concentration
and CHD. The findings should provide a comparison of the potential importance of sdLDL
versus sdLDL-C as etiological biomarkers for primary occurrence of CHD.
Methods
Data source and search
PubMed, MEDLINE (1946 to January 29, 2020), EMBASE (1974 to January 29, 2020), and
Web of Science were searched using the search terms for sdLDL, sdLDL-C, CHD, and the
measure of association presented in S1 Table in S1 File. Literature searches were limited to
English-language primary research publications in humans. The searches were supplemented
by screening reference lists of included studies and selected reviews. The search was conducted
by one investigator (LL). A review protocol does not exist.
Study eligibility criteria
Titles and abstracts were screened, and available English full texts were retrieved and examined
for inclusion. Any studies of a prospective or case control design which reported a measure of
association between sdLDL or sdLDL-C and incident CHD with serum (or plasma) samples
obtained before determination of outcomes were included. Prospective studies of people with
cardiovascular disease at baseline were excluded as first incidence of CHD was the outcome of
interest. Prospective studies and case control studies that investigated populations that had
other established diseases like diabetes or HIV were included provided there was no evidence
of previous cardiovascular disease. The outcome of interest, incidence of CHD, was defined
according to ICD10 codes I20-I25: a group of diseases that includes stable angina, unstable
angina, myocardial infarction, death due to any of the aforementioned cardiac events, and sud-
den coronary death [27]. The Grading of Recommendations Assessment, Development and
Evaluation (GRADE) tool [28] was used to assess risk of bias in each study (S2 Table in S1
File).
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Measurement of exposure
In this review, studies that quantified either the concentration of cholesterol within sdLDL par-
ticles (sdLDL-C) or the presence or concentration of sdLDL particles were included. Presence
was defined either as LDL classes III (1.044–1.060 g/ml), and IV (>1.060 g/ml) for studies that
used ultracentrifugation, LDL classes III A and B (small LDL, 24.2–25.5 nm) for studies that
used GGE, or fractions with a density from 1.044 to 1.063 g/ml for studies that used homoge-
nous assay methods.
Data extraction
Data were collated on population type (general vs. high-risk populations); mean age; sex; geo-
graphical location; study design; hypertension prevalence; diabetes prevalence; sample type
(serum vs. plasma); assay type; number of participants; and number of incident CHD events.
Detailed information about the study setting and the definition of CHD were also collected.
Measures of association (odds ratios and hazard ratios) between sdLDL or sdLDL-C and inci-
dent CHD were extracted with the following levels of covariate adjustment, when available: 1)
unadjusted, adjusted only for age and sex, or vague specification of adjusted covariates; 2)
adjusted for demographic factors and conventional CHD risk factors; and 3) adjusted for
demographic factors, conventional CHD risk factors, and other lipid levels. The measures of
association were standardized (S3 Table in S1 File).
Statistical analysis
All statistical analyses and visualization were performed in R 4.0 using “meta” [29] and
“ggplot2” [30], and a 2-sided p-value of<0.05 represented statistical significance. Original
measures of association and methods of standardization are reported in S3 Table in S1 File.
The assessment of publication bias was assessed graphically with funnel plots and Egger’s test.
For the primary analysis, adjusted odds ratios and hazard ratios for the association between
sdLDL-C and CHD were pooled by random effects inverse-variance weighted random effects
meta-analysis [31]. The random effects method was selected a priori due to anticipated hetero-
geneity in the populations studied and the design of included studies. The presence of between
study heterogeneity was assessed using the I2 statistic, a statistic that quantifies the percentage
of the total observed heterogeneity that is due to between-study variation. The Cochrane
Handbook suggests that an I2 between 30–60% may represent moderate heterogeneity and an
I2 between 50–90% may represent substantial heterogeneity [32].
Secondary analyses included random effects meta analyses subgrouping by adjustment level
(unadjusted and adjusted measures included) and study design. Potential explanatory covari-
ates such as location, population type, and assay method were explored as factors for heteroge-
neity using univariate meta-regression after adjusting for study design. One study provided
mean cholesterol concentration for each quartile, whereas two other studies provided the over-
all mean and standard deviation of cholesterol concentration. By assuming a normal distribu-
tion, the mean cholesterol concentration for each quartile were calculated. A conversion factor
of 0.02586 was used to convert from concentrations reported in mmol/L to mg/dL [1]. The
mean concentrations were plotted against the corresponding quartile hazard ratios for all
three studies. Dose-dependency between sdLDL levels and CHD could not be assessed due to
lack of data.
SK was supported by the British Heart Foundation (BHF) (RG/18/13/33946). LL did not
receive funding.
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Results
The literature search yielded 1,384 total citations, of which 858 were screened and ultimately
21 met eligibility criteria (Fig 1), reporting data on 30,628 participants (53.1% male) with
5,693 CHD events. Thirteen studies used sdLDL as their exposure (hereby referred to as
sdLDL studies), whereas the other seven used sdLDL-C (hereby referred to as sdLDL-C stud-
ies) and one used both. Nine studies were case control studies, five were nested case-control
studies, two were randomized controlled trials, and the remaining five were prospective cohort
studies. Studies were conducted in East Asia (n = 7), Europe (n = 6), and North America
(n = 8). Seven studies used a sample of the general population, and fourteen studied either hos-
pital participants, participants with type 2 diabetes, HIV, or liver disease. Ten studies measured
sdLDL-C/sdLDL using an automated chemical analyzer, seven with gel electrophoresis, and
four with nuclear magnetic resonance imaging (NMR). The included studies are summarized
in Table 1. More detailed descriptions of the study population, outcome definitions, covariate
adjustment are provided in S4 Table in S1 File. Further details of the sdLDL-C assays includ-
ing assessments of validity and limitations are reported in S5 Table in S1 File.
Fig 1. Systematic review PRISMA flow diagram.
https://doi.org/10.1371/journal.pone.0241993.g001
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Association of sdLDL/sdLDL-C with incident CHD
The random effects pooled OR for high vs low sdLDL (14 studies) was 1.36 (95% CI: 1.21,
1.52), with high heterogeneity I2 = 89% (Fig 2A). The relative risk for CHD comparing the top
versus the bottom quartiles of sdLDL-C (8 studies) was 1.07 (95% CI: 1.01, 1.12), with evidence
of substantial heterogeneity (I2 = 87%) (Fig 2B).
Association of sdLDL/sdLDL-C with incident CHD across subgroups
Subgroup analyses by adjustment level and study design were planned a priori. Study-specific
unadjusted and adjusted measures of association were first compared in a forest plot sub-
grouped by adjustment level (S1 Fig in S1 File). For the sdLDL studies, adjustment attenuated
the ORs with the exception of two studies [33,34]; however, these two studies adjusted for a
limited number of confounders. For the sdLDL-C studies, adjustment to any degree attenuated
Table 1. Summary of studies of association between sdLDL/sdLDL-C and CHD.
Author/Date Study Study Design Population Location sdLDL-C Assay Method Mean Age Sample Size (Cases) Males
sdLDL
Koba et. al 2002 A†[55] Showa CC Diabetes East Asia electrophoresis 60.3 348 (130) 348
Koba et. al. 2002 B† [33] Showa CC Diabetes East Asia electrophoresis 60.2 874 (571) 597
Bucher et. al. 2012 [6] SHCS NCC HIV Europe analyzer NR 490 (98) 385
Goliasch et. al. 2011 [56] MIVYA CC Hospital Europe electrophoresis 37.3� 302 (92) 263
Kuller et. al. 2002 [57] CHS CC Hospital North America NMR 73 373 (191) 0
Kwon et. al. 2006 [58] Yonsei CC Hospital East Asia electrophoresis 60.4 504 (262) NR
Mackey et. al. 2015 [59] WHI-OS NCC Hospital North America NMR 65.1 677 (124) 0
Mykannen et. al. 1999 [60] Kuopio NCC Diabetes Europe electrophoresis 69.2 258 (86) 129
Lamarche et. al. 1997 [61] QC NCC General North America electrophoresis 58 2103 (113) 2103
Otvos et. al. 2006 [39] VA-HIT NCC Veterans North America NMR 64.2 1061 (364) 1061
Russo et. al. 2014 [34] Messina CC Diabetes Europe analyzer 65.3 95 (59) 0
Williams et. al. (2013) [38] HATS RCT Hospital North America electrophoresis 53.6 142 (142) 125
Xu et. al. 2015‡ [62] FuWai CC Hospital East Asia electrophoresis 55.1 413 (293) 254
Zeljkovic et. al. 2008 [63] ICDCC CC Hospital Europe electrophoresis 55.7 359 (181) 216
sdLDL-C
Arai et. al. 2013 [5] Suita PC General East Asia analyzer 58.5 2034 (63) 968
Arsenault et. al. 2007 [64] EPIC-Norfolk NCC General Europe electrophoresis 65.7 2955 (1035) 1869
Higashioka et. al. 2019 [1] Hisayama PC General East Asia analyzer 63.2 3080 (79) 1290
Hoogeveen et. al. 2015 [46] ARIC PC General North America analyzer 62.8 10225 (1158) 4499
Siddiqui et. al. 2019 [65] CRLTR PC LTR North America NMR 58 130 (20) 81
Koba et. al. 2008 [7] Showa CC Hospital East Asia analyzer 60.5 871 (482) 612
Tsai et. al. 2014 [26] MESA PC General North America analyzer 60.7 3334 (150) 1473
�Only reported median
†A refers to Atherosclerosis study; B refers to Am Heart J study
‡Xu et. al. reported both sdLDL and sdLDL-C estimates Abbreviations: PC = prospective cohort study; NCC = nested case-control study; CC = case-control study;
LTR = liver transplant recipients; NR = not reported; NMR = nuclear magnetic resonance imaging; analyzer = automated chemical analyzer; electrophoresis = gel
electrophoresis Full Study Names: Suita = Suita Study, EPIC-Norfolk = European Prospective Investigation into Cancer in Norfolk Prospective Population Study;
SHCS = Swiss HIV Cohort Study; MIVYA = Myocardial Infarction Survivors in Very Young Adults Study; CHS = Cardiovascular Health Study; Hisayama = Hisayama
Study; ARIC = Atherosclerosis Risk in Communities Study; Showa = Showa Study; QBC = Quebec Cardiovascular Study; VA-HIT = Veterans Affairs High-Density
Lipoprotein Intervention Trial; Messina = Messina Study; HATS = HDL-Atherosclerosis Treatment Study; MESA = Multi-Ethnic Study of Atherosclerosis;
Yonsei = Yonsei Study; WHI-OS = The Women’s Health Initiative Observational Study; Kuopio = Kuopio Study; CRLTR = Cardiometabolic Risk in Liver Transplant
Recipients Study; ICDCC = Institute of Cardiovascular Diseases, Clinical Centre of Serbia Study
https://doi.org/10.1371/journal.pone.0241993.t001
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the OR to the null (range of % attenuation: 2.3–114.9), although there was no evidence the
adjustment extent was associated with the magnitude of attenuation.
The pooled hazard ratio for the nested case-control subgroup (4 studies) provided no evi-
dence of association; 1.03 (95% CI: 0.91, 1.16), although the heterogeneity was low (I2 = 7%).
The pooled hazard ratio for the case-control subgroup (8 studies) provided evidence of an
association; 1.55 (95% CI: 1.29, 1.86), with substantial heterogeneity (I2 = 91%) (Fig 3A). The
pooled hazard ratio for the randomized controlled trial subgroup (2 studies) provided evi-
dence of an association; 1.76 (95% CI: 1.33, 2.32), with no heterogeneity. There was evidence
of publication bias (Egger’s test: 4.4, p-value = 7.9x10-4) (S2A Fig in S1 File) The pooled haz-
ard ratio for the prospective cohort subgroup in sdLDL-C studies (5 studies) was 2.83 (95% CI:
1.57, 5.09) and 1.01 (95% CI: 0.99, 1.04) for the case-control subgroup (Arsenault et. al. was
classified as a case-control) (3 studies). The heterogeneity lowered from 85% to 71% for the
prospective cohort subgroup (Fig 3B). There was evidence of publication bias (Egger’s test:
14.8, p = 6.1x10-6) (S2B Fig in S1 File).
Univariate meta-regressions for location, assay method, population type and publication
year were performed after adjusting for study design for studies reporting sdLDL (S6 Table in
S1 File) and sdLDL-C (S7 Table in S1 File). The results showed that sdLDL studies using
European populations and sdLDL-C studies using unhealthy populations or gel
Fig 2. Forest plots for random effects meta-analysis of the associations between (A) sdLDL, (B) sdLDL-C and CHD. ‘+’ = adjusted for
other lipid subfractions; ‘++’ = adjusted for demographics and lifestyle risk factors; ‘+++’ = adjusted for demographics, lifestyle risk factors
and lipid subfractions. Maximally adjusted hazard ratios from each study were used. Kuller et. al. provided an unadjusted estimate only.
https://doi.org/10.1371/journal.pone.0241993.g002
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electrophoresis methods tended to report lower measures of association. sdLDL-C studies
using North American populations tended to report slightly higher measures of association.
Interestingly, location and population type individually appeared to explain 56% and 72% of
the variability in reported measures of association in sdLDL-C studies respectively.
Assessment of a dose-response relationship
In each of three studies that provided information on quartiles of sdLDL-C, there was a signifi-
cant trend association found across quartiles, providing evidence of a dose-dependent rela-
tionship between sdLDL-C and risk of CHD (Fig 4).
Discussion
This systematic review and meta-analysis of adjusted association estimates from 19 observa-
tional studies and 2 randomized suggests that the presence of sdLDL is associated with
increased risk of developing CHD. This association was independent of conventional cardio-
vascular risk factors and other lipid subfractions, as well as consistent across different measure-
ment methods. Furthermore, there was some evidence of a dose-response relationship with
sdLDL-C concentration, albeit heterogeneous across studies. The pooled association between
sdLDL-C and incident CHD was also independent of conventional cardiovascular risk factors
and other lipid subfractions, as well as consistent across geographical regions. Interestingly,
when subgrouped by adjustment level, the sdLDL studies that had adjusted for LDL-C (an
established lipid biomarker), had a non-statistically significant pooled estimate of 1.54 (95%
CI: 0.97, 2.43). However, this could be due to chance in the 21 studies included (5,693 CHD
cases) and requires more powerful analyses to more conclusively assess whether sdLDL has no
prognostic value in addition to established lipid biomarkers. The pooled estimate for CHD
risk in prospective cohort studies was 2.83 (95% CI: 1.57, 5.09). In addition, sdLDL does seem
to have high discriminative potential as several studies reported area under the curves (AUC)
between sdLDL and CHD as low as 0.641 [35] and as high as 0.83 [36] in a Chinese and Indian
cohort respectively, which suggests that sdLDL has a high sensitivity and specificity of predict-
ing CHD. sdLDL also has a fairly high AUC, 0.74, in diabetic participants [37].
The strongest evidence for the potential of sdLDL as a biomarker come from randomized
controlled trial results. Williams et. al. not only found that lower sdLDL was independently
associated with lower risk of CHD in the HATS trial, but also that simvastin and niacin signifi-
cantly reduced the levels of sdLDL by 29% (p-value = 0.002) [38]. In addition other trials such
as VA-HIT [39] and a trial conducted in hypercholesterolemia patients [40] showed that other
treatments besides statins (gemfibrozil, a fibric acid derivative, and mipomersen, an apoB
inhibitor) predominantly reduced the concentration of sdLDL particles. Taken together, this
suggests that sdLDL may be a potential target for lipid-lowering interventions. While the
American Heart Association currently recommends treatment based on a patient’s LDL-C lev-
els (> 160 mg/dL) [41], given the existing body of evidence from RCTs, a similar guideline
could be suggested for sdLDL. The European Society of Cardiology (ESC) and European Ath-
erosclerosis Society (EAS) have characterized a pattern of dyslipidemias (termed the athero-
genic lipid triad) which predispose premature CVD, characterized by increased LDL/
triglyceride levels, increased sdLDL levels, and reduced high-density lipoprotein-cholesterol
levels (Level B evidence, Class IIa recommendation) [42]. Existing data on the association
between sdLDL and CHD come from mostly large non-randomized studies and two recent
RCTs, and thus the weight of the evidence in favor of treatment based on sdLDL should be
considered. Further evidence on the causal association between sdLDL-C and CHD is moti-
vated, given that there only exist randomized controlled trials studying sdLDL. However,
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Fig 3. Forest plots of association between (A) sdLDL, (B) sdLDL-C and CHD subgrouped by study design. PC = prospective cohort study;
CC = case-control study; NCC = nested case-control study; RCT = randomized controlled trial.
https://doi.org/10.1371/journal.pone.0241993.g003
PLOS ONE Small, dense LDL-cholesterol and coronary heart disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0241993 November 9, 2020 9 / 16
considering the biological evidence, extant observational evidence, extant RCT evidence and
an increasing amount of genetic evidence, studying both sdLDL and sdLDL-C-lowering inter-
ventions on CHD risk to investigate their biomarker potential is indicated.
Mendelian Randomization (MR) is a widely agreed upon approach to establish temporal
causal evidence due to the random allocation of alleles and their precedence before potential
confounders in a lifetime [43]. Previously, GWAS analysis identified SNPs clustered at 8 differ-
ent loci on chromosomes 1, 2, 7, 8, 11 and 19 that were significantly associated with sdLDL-C
[44]. For instance, one such SNP, rs4420638, was found to be associated with lipoprotein-asso-
ciated phospholipase A2, which generates proinflammatory and proatherogenic compounds
in the arterial wall and is considered a potential therapeutic target for CHD [45]. Furthermore,
Hoogeveen et. al. found the SNP rs508487 located in the PCSK7 gene (implicated in internali-
zation of LDL receptors) to be significantly associated with sdLDL-C at the genome-wide level
in a GWAS of the Atherosclerosis Risk in Communities cohort [46]. It is plausible that PCSK7
is involved with modulating circulating lipid levels and may hold promise as another therapeu-
tic target for CHD. Zhao et. al. found that the SNPs for sdLDL (OR: 1.45; p-value = 0.043) and
sdLDL-C (OR: 1.43; p-value = 0.042) were significant predictors of CHD in their multivariable
MR analysis tested in the CARDIOgGRAMplusC4D and UK Biobank datasets adjusted for
HDL, LDL-C and triglycerides, although they do not specify which SNPs [47]. Further, they
did not find statistical evidence for horizontal pleiotropy for the SNPs associated with sdLDL,
which lends credence to the validity assumption of those SNPs as instrumental variables.
Fig 4. Dose-dependent relationships in three studies that report quartiles of sdLDL-C. The numbers 1–4 represent the quartiles. The
quartiles used by Arai are�19.8, 19.8–30.6, 30.6–41.7, 41.7–63.3. The calculated quartiles for Hoogeveen are�35.8, 35.8–41.5, 41.5–45.4,
45.4–51.2 and for Tsai,�15.9, 15.9–32.0, 32.0–43.0, 43.0–59. The size of the square represents the sample size, with Hoogeveen having the
largest sample size (n = 10,225).
https://doi.org/10.1371/journal.pone.0241993.g004
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Ference et. al. also demonstrated via MR that triglyceride-lowering lipoprotein lipase variants
and low-density lipoprotein cholesterol-lowering variants were associated with lower risk of
CHD per 10-mg/dL of apolipoprotein B-containing lipoproteins [48]. Given the hypothesized
mechanism between lipase and sdLDL formation, it would be informative to similarly assess
the association between sdLDL-lowering variants and risk of CHD.
sdLDL and sdLDL-C may be useful as biomarkers to identify high-risk individuals and
allow for early prevention as studied for LDL-C via a combination of diet and exercise [49]
and statin therapy [50], although such an approach would require further investigation. Specif-
ically, with diet, an emerging field of research aims to understand the metabolomics of lipo-
proteins following a postprandial lipemia response to a meal. Standard fasting conditions
prior to bloodwork are not necessarily representative of normal lifestyles. Although it has been
hypothesized that hepatic lipase activity increases postprandially and results in the formation
of more sdLDL particles, several studies have not been able to demonstrate a statistically signif-
icant increase in sdLDL levels [51,52]. Clinically, sdLDL has already gained some recognition
as a potential biomarker by the National Cholesterol Education Program (NCEPIII) [17]. The
mechanisms triggering the release of sdLDL in people without clinically manifest CHD still
remain unclear. It is speculated that low plasma triglyceride levels in participants with familiar
hypercholesterolemia [53] or hypertriglyceridemia [21] may affect apolipoprotein metabolic
regulatory networks which promote elevated levels of circulating sdLDL.
Study strengths and limitations
This study is the first meta-analysis of available evidence from observational studies investigat-
ing the association between sdLDL/sdLDL-C and CHD using standardized measures of associ-
ation to allow for comparison. We pooled data from 21 studies with a total of 30,628 subjects
and 5,693 incident CHD events, providing substantial statistical power.
There were a number of limitations that warrant discussion. Even though the heterogeneity
was fairly high amongst both sdLDL and sdLDL-C studies, the random effects meta-analysis
was conducted and interpreted because there was no inconsistency in the direction of the
effect, but rather its magnitude. Misclassification bias may occur to a different extent across
studies as CHD diagnosis has likely changed over time and may vary from doctor to doctor,
which may contribute to the observed between-study heterogeneity. Bias from measurement
error may occur since sdLDL and sdLDL-C were measured using different methods, and cer-
tain studies only performed one measurement [1,5], which may result in OR’s attenuated
towards the null. The funnel plots and Egger’s tests suggested some evidence of publication
bias present within the studies with smaller sized studies tending to report more extreme esti-
mates. Adjustment for confounding was not to the same extent in all studies, which may con-
tribute to heterogeneity (S1 Fig in S1 File). It was difficult to judge across studies whether
adjustment attenuated the association towards the null overall as sample sizes in unadjusted
and adjusted models often differed within studies. Furthermore, some studies may have
adjusted for mediators (namely other lipids whose position on the causal pathway is unclear),
potentially leading to vastly attenuated association estimates. One potential residual con-
founder was socioeconomic status, which has been widely studied as risk factor for CHD [54].
Further, all included studies were conducted in North America, Europe, or East Asia which
limited generalizability. The extent of validity of the assumption of a normally distributed
exposure variable and a linear association with the outcome of interest could only be approxi-
mately inferred and generalized from few available study-specific evidence, including only one
study reviewed that reported a normal distribution of sdLDL-C and approximate dose-
response plots constructed from reported estimates. Thus, this study is unable to determine
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whether there exists a dose-dependent risk or a threshold risk based on the concentration of
sdLDL-C or sdLDL particles. Different studies used different quartile cutoffs potentially limit-
ing comparability between these studies that may be more concerning if the exposure distribu-
tions differ greatly across studies. Important limitations of each study reviewed are listed in S8
Table in S1 File. Finally, we did not include studies recording other cardiovascular outcomes
(i.e. non-CHD), which limits the conclusions drawn from this study on the prognostic value of
sdLDL and sdLDL-C to primary prevention of CHD.
Conclusions
Both sdLDL and sdLDL-C are associated with higher CHD risk. The results are concordant
with research investigating related lipids and is supported by biological evidence of sdLDL’s
atherogenic potential, dose response evidence as well as genetic association studies. The impli-
cations are that while sdLDL/sdLDL-C may be useful as a risk marker, further research needs
to be done to assess whether it is a suitable therapeutic target independent of well-known lipid
metabolism pathways that have proven target therapies. Future research should aim to better
characterize the dose-dependency between sdLDL levels and CHD, which could not be
assessed due to lack of detailed information and investigate whether the simultaneous determi-
nation of sdLDL and sdLDL-C concentrations improve prognosis of CHD risk.
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